Total medical devices industry venture financing deals worth $1.22bn were announced in the US in March 2021, led by $125m venture financing of Paige.AI, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 48.6% over the previous month of $821.16m and a rise of 45.01% when compared with the last 12-month average of $841.34m.
The US held a 67.03% share of the global medical devices industry venture financing deal value that totalled $1.82bn in March 2021.
In terms of venture financing deal activity, the US recorded 60 deals during March 2021, marking an increase of 15.38% over the previous month and a rise of 9.09% over the 12-month average.
US medical devices industry venture financing deals in March 2021: Top deals
The top five medical devices industry venture financing deals accounted for 37.4% of the overall value during March 2021.
The combined value of the top five medical devices venture financing deals stood at $457m, against the overall value of $1.22bn recorded for the month.
The top five medical devices industry venture financing deals of March 2021 tracked by GlobalData were:
1) Casdin Capital, Catalio Capital Management, Johnson & Johnson Innovation – JJDC and KKRInc’s $125m venture financing of Paige.AI
2) The $102m venture financing of Inflammatix by D1 Capital Partners, Khosla Ventures, Northpond Ventures, OSF Ventures and Think.Health(Think.Health Ventures)
3) Alumni Ventures Group, aMoon Partners, Echo Health Ventures, Khosla Ventures and Northpond Ventures’ $82m venture financing of Scipher Medicine
4) The $75m venture financing of iXlayer by Anne Wojcicki, Bobby Yazdani, Dara Khosrowshahi, General Catalyst Partners, Hamid Moghadam, Pear Ventures and Zeshan Muhammedi
5) Deerfield ManagementLP, ION Crossover Partners and Omega Capital Partners’ venture financing of HAPPIFY HEALTH for $73m.